Tikcro Technologies (TIKRF) has an investment in BioCancell Therapeutics Inc. (XTAE:BICL) through which the company is engaged in the discovery, development and commercialization of therapies to treat solid cancer tumors. It trades at roughly 50% of net cash and at an EV/EBIT ratio of 5.51x. There is no doubt the company has been something of a value trap over the past decade:
GuruFocus already reported on Steven N. Bronson taking action against the incumbent management in 2007, and he appears to have made some headway as a different CEO has been installed in the meantime. Bronson continues to hold approximately 16% of shares.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.